Key points are not available for this paper at this time.
Our results demonstrate the distinct clinical and molecular features and clinical outcomes of HER2-low breast tumors.
Zhang et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: